Table 2. Results of the Model Analysis in the Whole Cohort Investigating the Longitudinal Changes of the Respective Biomarkers in Cerebrospinal Fluid (CSF) and Plasma for Each Drug.
| Yeara | Sample size | Estimated least-squares mean change from baseline | SE (95% CI) | P value |
|---|---|---|---|---|
| CSF neurogranin, pg/mL | ||||
| Gantenerumab | ||||
| 1 | 44 | −21.863 | 48.04 (−117.44 to 73.71) | .65 |
| 2 | 40 | −51.785 | 60.72 (−172.60 to 69.03) | .40 |
| 4 | 28 | −242.430 | 63.68 (−369.12 to −115.73) | <.001 |
| Solanezumab | ||||
| 1 | 38 | 1.182 | 53.87 (−106.16 to 108.53) | .98 |
| 2 | 35 | 8.507 | 63.98 (−118.98 to 135.99) | .90 |
| 4 | 30 | 23.712 | 96.44 (−168.44 to 215.87) | .81 |
| CSF sTREM2, ng/mL | ||||
| Gantenerumab | ||||
| 1 | 44 | 0.636 | 0.33 (−0.02 to 1.29) | .06 |
| 2 | 40 | 1.123 | 0.43 (0.26 to 1.99) | .01 |
| 4 | 28 | 1.063 | 0.52 (0.03 to 2.09) | .04 |
| Solanezumab | ||||
| 1 | 39 | 0.021 | 0.47 (−0.91 to 0.96) | .97 |
| 2 | 36 | −0.026 | 0.42 (−0.86 to 0.81) | .95 |
| 4 | 30 | 0.436 | 0.59 (−0.73 to 1.61) | .46 |
| CSF YKL-40, ng/mL | ||||
| Gantenerumab | ||||
| 1 | 44 | 7.196 | 4.86 (−2.47 to 16.86) | .14 |
| 2 | 40 | 13.795 | 8.38 (−2.88 to 30.47) | .10 |
| 4 | 28 | 16.822 | 9.39 (−1.86 to 35.50) | .08 |
| Solanezumab | ||||
| 1 | 40 | 8.994 | 10.70 (−12.32 to 30.31) | .40 |
| 2 | 37 | 5.394 | 9.83 (−14.19 to 24.98) | .59 |
| 4 | 30 | 19.511 | 13.28 (−6.93 to 45.96) | .15 |
| CSF GFAP, ng/mL | ||||
| Gantenerumab | ||||
| 1 | 45 | −0.105 | 0.36 (−0.82 to 0.61) | .77 |
| 2 | 41 | 0.024 | 0.40 (−0.78 to 0.83) | .95 |
| 4 | 29 | 4.713 | 6.55 (−8.32 to 17.74) | .47 |
| Solanezumab | ||||
| 1 | 40 | −0.156 | 0.40 (−0.95 to 0.64) | .70 |
| 2 | 36 | 0.434 | 0.39 (−0.34 to 1.21) | .27 |
| 4 | 30 | 0.941 | 0.64 (−0.34 to 2.22) | .15 |
| CSF NfL (log) | ||||
| Gantenerumab | ||||
| 1 | 44 | −0.016 | 0.04 (−0.09 to 0.06) | .66 |
| 2 | 40 | −0.019 | 0.04 (−0.09 to 0.05) | .61 |
| 4 | 28 | −0.053 | 0.06 (−0.17 to 0.06) | .35 |
| Solanezumab | ||||
| 1 | 40 | −0.002 | 0.07 (−0.14 to 0.13) | .97 |
| 2 | 37 | 0.068 | 0.04 (−0.01 to 0.15) | .10 |
| 4 | 30 | 0.143 | 0.06 (0.03 to 0.26) | .02 |
| Plasma GFAP, ng/mL | ||||
| Gantenerumab | ||||
| 1 | 20 | −0.019 | 0.01 (−0.03 to 0) | .02 |
| 2 | 20 | −0.025 | 0.01 (−0.04 to −0.01) | .002 |
| 4 | 13 | −0.058 | 0.02 (−0.09 to −0.03) | <.001 |
| Solanezumab | ||||
| 1 | 18 | −0.006 | 0.01 (−0.02 to 0.01) | .47 |
| 2 | 19 | −0.023 | 0.01 (−0.05 to 0) | .10 |
| 4 | 9 | −0.007 | 0.03 (−0.06 to 0.05) | .80 |
| Plasma NfL (log) | ||||
| Gantenerumab | ||||
| 1 | 18 | −0.032 | 0.09 (−0.21 to 0.15) | .72 |
| 2 | 19 | −0.035 | 0.11 (−0.25 to 0.18) | .74 |
| 4 | 13 | −0.180 | 0.13 (−0.45 to 0.09) | .19 |
| Solanezumab | ||||
| 1 | 17 | −0.085 | 0.08 (−0.24 to 0.07) | .29 |
| 2 | 18 | −0.012 | 0.15 (−0.31 to 0.29) | .94 |
| 4 | 8 | −0.020 | 0.17 (−0.36 to 0.32) | .91 |
Abbreviations: GFAP, glial fibrillary acidic protein; NfL, neurofilament light protein; sTREM2, soluble triggering receptor expressed on myeloid cells 2; YKL-40, chitinase 3–like protein 1.
a
Each year represents the time duration of drug administration since the initial biomarker assessment at baseline.